Shares of Procter & Gamble have retraced to levels not seen in over two years, with the stock recently touching its lowest point since early 2021. This contraction reflects broader concerns over slower organic sales growth—P&G posted just 1.5% top-line expansion in the most recent quarter—but investors may have already priced in these underwhelming results. Against this backdrop, the company continues to generate strong free cash flow of more than $15 billion annually and maintains a dividend yield near 2.8%, underscoring its ability to compound value even during periods of muted revenue momentum.

In its latest 13F filing, GDS Wealth Management disclosed a 20.9% increase in its Procter & Gamble stake during the third quarter, adding 14,060 shares for a total holding of 81,190 shares. This transaction elevated GDS’s P&G exposure to approximately $12.5 million at quarter-end. Several other institutions mirrored this bullish stance: BAM Wealth Management initiated a new position valued at $678,000; Acorn Wealth Advisors upped its stake by 4.5%, now holding 4,028 shares; and PFG Investments added 870 shares, bringing its total to 54,237. Overall, nearly two-thirds of P&G’s float is held by institutional investors, highlighting confidence in the company’s defensive cash flows and dividend track record.

Analysts have grown more constructive on Procter & Gamble’s outlook over the past month. JPMorgan Chase upgraded the stock from Neutral to Overweight and raised its 12-month target, citing resilient demand in the home care and personal grooming segments. UBS followed suit with a Buy rating and a similar uptick in its target, while Piper Sandler’s initiation of Neutral coverage underscored stability in P&G’s categories. Despite one downward revision from Raymond James, the consensus across 22 brokerages remains a Moderate Buy, with an average price objective implying mid-single-digit upside from current levels.